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Abstract
Purpose Catheter ablation is considered the mainstay treatment for drug-refractory atrial fibrillation (AF). The aims of our study
were to compare the efficacy and safety of the most two currently approved approaches (point-by-point radiofrequency ablation
(RFA), either with contact force (CF) or without contact force (nCF) catheters, and cryoballoon ablation (CBA)) in the Veterans
Healthcare System.
Methods We performed a retrospective study of patients who underwent ablation for treatment of AF at the veterans affairs
healthcare system between 2013 and 2018. Only the first reported ablation procedure was included.
Results We included 956 patients in the study (97.4% males, 91.5% Caucasians, 67% paroxysmal AF), with 682 patients in
RFA-nCF, 139 in RFA-CF, and 135 in CBA. Thirty-day complication rates were comparable between the three groups with the
exception of higher incidence of phrenic nerve injury in CBA group when compared to RFA-nCF (2.2% vs 0.0%, p < 0.01).
Long-term recurrence rate of AF was significantly lower in the CBA group when compared to RFA-nCF (33.3% vs 47.7%,
adjusted HR 0.60, 95% CI 0.44–0.83, p < 0.01). On the other hand, it was similar between RFA-CF and RFA-nCF groups (43.9%
vs 47.7%, adjusted HR 1.01, 95% CI 0.76–1.33, p 0.97). After stratifying patients based on AF type, these findings were only
present in patients with paroxysmal AF.
Conclusion CBA for paroxysmal AF, in male dominant patients’ population, was associated with lower incidence of AF
recurrence rate while having a comparable safety profile to RFA independent of the use of CF catheters.
Keywords Atrial fibrillation . Radiofrequency ablation . Cryoballoon ablation . Contact force
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Atrial fibrillation (AF) is an endemic disease and age-related
cardiac arrhythmia. In the recent 2017 expert consensus statement, catheter ablation of drug-refractory paroxysmal AF
carries a class I level A indication, and pulmonary vein electrical isolation (PVI) is still the cornerstone approach [1].
The most common procedure for PVI is percutaneous
catheter-based approach which is achieved by creating tissue
necrosis and scar formation through circumferential lesions
surrounding the pulmonary veins. The most two currently
approved catheter approaches for PVI for paroxysmal AF in
the USA are point by point radiofrequency ablation (RFA)
and cryoballoon ablation (CBA) which is considered a “single-shot” approach. Prior randomized clinical trials showed
comparable efficacy and safety profile between the two studies during overall short duration follow-up [2]. CBA has
emerged as a novel treatment for pulmonary vein isolation
(PVI) for patients with paroxysmal AF. The second-
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generation Arctic Front Advance (ADV) was redesigned with
technical modifications aiming at procedural and outcome improvements. On the other hand, advancement in RFA catheter
design resulted in the development of contact sensing catheters which, in theory, gives the operator the ability to assure
adequate tissue contact prior to delivering the ablation lesions
[3]. Few studies have compared the efficacy and safety of
these three approaches. We aimed to evaluate the long-term
outcome of the two types of RFA (contact force (CF) and noncontact force (nCF)) versus CBA in the Veterans Affairs (VA)
healthcare system in our current retrospective multicenter
study.

was further subdivided into two groups based on the use of
contact force sensing catheters during the PVI ablation. We
also identified the use of different ablation techniques, namely, PVI; superior vena cava (SVC) isolation; mitral valve and/
or roof line; cavotricuspid isthmus (CTI) ablation; and complex fractionated atrial electrograms (CFAE) ablation. In patients who underwent a redo ablation procedure, if at least one
PV showed evidence of reconnection that required additional
ablation to achieve reisolation, they are considered to have
undergone additional PVI.

2.4 Outcomes

2 Methods
2.1 Data source and study population
Using data from CAPRI (Compensation and Pension Record
Interchange) system, we identified patients who underwent
AF ablation between January 2013 and January 2018.
CAPRI is an electronic health record system holding national
data for the VA system in the USA and allows electronic
search as well as review of notes, procedures, imaging reports,
and lab results across various VA hospitals. We initially
narrowed our search by identifying patients with the procedure code CPT 93656. We used a combination of electronic
data search (using ICD codes) and manual verification to identify demographic data and baseline clinical variables at the
time of ablation. We manually reviewed each chart and excluded ablations for other forms of supraventricular tachycardias. The following information was collected: demographic
data, co-morbidities, medications used, type of AF, type of
ablation, complications in the first 30 days, time to first recurrence, re-ablation, direct current cardioversion (DCCV) postablation, and all-cause mortality. The Central Arkansas VA
Health System’s institutional review board approved the
study.

2.2 Types of atrial fibrillation
We classified AF into two types: paroxysmal and non-paroxysmal. The non-paroxysmal group included patients with persistent and long-term persistent AF [4]. The patient assignment was based on documentation in the treating physician
notes. If the type was not specified, the allocation was then
performed by the reviewer based on the information available
in the chart.

2.3 Type of ablation procedure
We divided patients into two groups based on ablation energy
source: RFA ablation group and CBA group. The RFA group

We evaluated the incidence of complications and mortality in the first 30 days after ablation and first AF recurrence. AF recurrence was counted following 3-month
blanking period after ablation. We also assessed the incidence and timing of re-ablation procedures or DCCV after
the index ablation. Any detection of AF beyond the
blanking period regardless of the duration was considered
a recurrence. Mode of detection included ECG report
showing AF, Holter, or event monitor, or implantable device interrogation with physician interpretation reporting
AF or a physician note documenting recurrence.

2.5 Statistical analysis
Patients were classified into three groups based on the energy
type used and the use of contact force sensing catheters: RFAnCF, RFA-CF, and CBA groups. Categorical variables are
reported as counts and percentages; differences were assessed
with Chi-square test or Fisher exact test (if n less than 5 for one
or more expected values). Continuous variables are presented
as means with one standard deviation; differences were compared with two sample Student’s t test. Kaplan-Meier analysis
and log-rank tests were used to compare the rates of AF recurrence and all-cause mortality for the unadjusted data. We
then performed Cox-regression analysis to adjust for baseline
variables and calculate the adjusted hazard ratios. The variables used in the Cox-regression analysis were age at ablation,
gender, race, co-morbidities (congestive heart failure, coronary artery disease (CAD), history of atrial flutter, diabetes
mellitus (DM), hyperlipidemia, hypertension, cerebrovascular
accidents (CVA), peripheral vascular disease (PVD), chronic
obstructive pulmonary disease, obstructive sleep apnea, and
chronic kidney disease), ever smoking status, prior ablation,
and body mass index. We chose the RFA-nCF group as the
reference group for comparing the other two groups.
A two-sided p value of equal to or less than 0.05 was
considered significant. Analysis was performed using IBM
SPSS statistics software.
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3 Results

3.2 Ablation procedure characteristics

3.1 Baseline characteristics

All patients (100%) in CBA group underwent successful PVI
using the second-generation CB catheter (Arctic Front
Advance®; Medtronic, Inc.). On the other hand, in the RFA
groups, one patient in each group did not have PVI as they
developed pericardial effusion requiring termination of the
procedure. Nine patients (6.7%) in the CBA groups required
additional RFA to complete the left atrial ablation. Mitral
valve and/or roof line (5.2% vs 15.5%, p < 0.01) and CFAE
(0.0% vs 5.9%, p < 0.01) were performed infrequently, as
expected, in the CBA group compared to the RFA-nCF group;
however, they were performed in similar frequency between
the RFA-nCF and RFA-CF groups. There is no statistical
difference in CTI line ablation between the three groups
(Supplementary material online, Table S1). Additional ablation beyond PVI (other than CTI) was performed more frequently in patients with persistent AF compared to paroxysmal AF (28.8% vs 12.5%, p < 0.01). In patients with persistent
atrial fibrillation, the frequency of ablation beyond PVI (other
than CTI) was still lower in the CBA group when compared to

A total of 956 patients who underwent first AF ablation
in the time period specified above from 34 VA centers
were included in this analysis. Of those, 682 patients
had RFA ablation with nCF catheters, 139 had RFA
with CF catheters, and 135 had CBA. More than 95%
of patients in all groups were males. More than 65% of
the patients had paroxysmal AF. Table 1 compares the
baseline characteristics between the three groups.
Compared to the RFA-nCF group, mean age in the
RFA-CF group was higher (65.7 SD 7.0 vs 63.7 SD
8.2 years, p 0.01), with a higher prevalence of prior
CVA (26.6% vs 18.2% p 0.02) and atrial flutter
(62.6% vs 53.4%, p 0.05). The CBA group had more
patients with CAD (67.4% vs 54.4%, p 0.01), DM
(48.1% vs 38.0%, p 0.03), hyperlipidemia (88.9% vs
82.1%, p 0.05), and PVD (8.1% vs 3.5%, p 0.02) when
compared to the RFA-nCF group.

Table 1 Baseline characteristics
Type of ablation
p value

p value

RFA-nCF*

RFA-CF

(682)

(139)

64 (8)
667 (97.8%)
624 (91.5%)
275 (40.3%)
371 (54.4%)
259 (38.0%)
276 (40.5%)
560 (82.1%)
24 (3.5%)
124 (18.2%)
231 (33.9%)
300 (44.0%)
240 (35.2%)
364 (53.4%)

66 (7)
133 (95.7%)
125 (89.9%)
52 (37.4%)
77 (55.4%)
59 (42.4%)
57 (41.0%)
115 (82.7%)
7 (5%)
37 (26.6%)
53 (38.1%)
69 (49.6%)
55 (39.6%)
87 (62.6%)

0.01
0.15
0.55
0.52
0.83
0.32
0.91
0.86
0.39
0.02
0.34
0.22
0.33
0.05

64 (7)
131 (97.0%)
126 (93.3%)
52 (38.5%)
91 (67.4%)
65 (48.1%)
53 (39.3%)
120 (88.9%)
11 (8.1%)
30 (22.2%)
50 (37.0%)
58 (43.0%)
52 (38.5%)
81 (60.0%)

0.72
0.59
0.48
0.70
0.01
0.03
0.79
0.05
0.02
0.27
0.48
0.83
0.46
0.16

Prior AF ablation

120 (17.6%)
129 (18.9%)

28 (20.1%)
18 (12.9%)

0.48
0.10

17 (12.6%)
20 (14.8%)

0.16
0.26

Paroxysmal AF
BMI ≥ 30

455 (66.7%)
414 (60.1%)

87 (62.6%)
82 (59.0%)

0.35
0.71

98 (72.6%)
82 (60.7%)

0.18
0.99

Age, years (SD)
Male
Caucasian race
CHF
CAD
DM
HTN
Hyperlipidemia
PVD
CVA
COPD
OSA
Ever smoking
Atrial flutter
CKD†

CBA
(135)

*

Reference group

†

CKD chronic kidney disease, defined as eGFR < 60 mL/min/1.73 m2

AF atrial fibrillation; BMI body mass index; CAD coronary artery disease; CBA cryoballoon ablation; CHF
congestive heart failure; COPD chronic obstructive pulmonary disease; CVA cerebrovascular accident; DM
diabetes mellitus; HTN hypertension; OSA obstructive sleep apnea; PVD peripheral vascular disease; RFA-CF
radiofrequency ablation-contact force; RFA-nCF radiofrequency ablation-non-contact force
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the RFA-nCF group (10.8% vs 29.1%, p 0.02) but was not
different between the RFA-nCF and RFA-CF groups (29.1%
vs 40.4%, p 0.11).

3.3 Outcomes
3.3.1 Thirty-day complication rates and all-cause mortality
There is no statistical difference in complication rates and allcause mortality (Table 2) among the three groups at 30-day
post-ablation with the exception of higher incidence of phrenic nerve injury (PNI) in CBA group when compared RFAnCF (2.2% vs 0.0%, p < 0.01). All PNI recovered spontaneously during follow-up (two recovered prior to hospital discharge from the index ablation and one within 1-year of follow-up). There was a higher overall incidence of pericardial
effusion in the RFA-CF when compared to RFA-nCF (3.6%
vs 1.2%, p 0.04), but there was no statistically significant
difference in major pericardial effusion requiring interventions (2.9% vs 1%, p 0.10).
3.3.2 Redo ablation, DCCV, and antiarrhythmic medication
use after index ablation
During the blanking period post-ablation, atrial tachyarrhythmia rates were not different among the groups. However, fewer patients in the CBA group underwent DCCV compared to
RFA-nCF (3.7% vs 9.2%, p 0.03).
Over a median follow-up of 39.7 months, 120 patients
underwent a redo ablation; PVI was reperformed in 96.7%
of procedures. In RFA-nCF group, 92 (13.5%) patients

Table 2 30-day complication
rates

underwent redo ablation, and almost all (98.9%) required
additional PVI. On the other hand, 24 patients (16.5%) in
RFA-CF group underwent a redo ablation and 87.5% required redo PVI. Only 4 (3.0%) patients underwent redo
ablation in the CBA group, but all of them required additional PVI. Patients in CBA group less commonly
underwent redo ablations when compared to the RFAnCF group (3.0% vs 13.5%, p < 0.01). This difference
was significant only in those with paroxysmal AF (1%
vs 13%, p < 0.01), but not in those with persistent AF
(8.1% vs 14.1%, p 0.44). On the other hand, the difference in redo ablation rates between the RFA-CF and
RFA-nCF was not statistically different, both in the overall cohort (17.3% vs 13.5%, p 0.24) and in patients with
paroxysmal AF (11.5% vs 13.0%, p 0.71). However, in
patients with persistent AF, the rate of redo ablation is
higher in the RFA-CF group compared to RFA-nCF
(26.9% vs 14.1%, p 0.03) (Supplementary material
online, Table S2). Atrial tachycardia or flutter was reported in 31 patients (25.8%) at time of the redo procedures,
while the rest had only atrial fibrillation. The rates were
not statistically significant between the three groups
(22.8% vs 37.5% vs 25%, p 0.34, nCF vs CF vs CBA,
respectively).
Although there was no statistical difference among the
three groups in regards to classes I and III antiarrhythmic
medication use at hospital discharge, 12 months, 24 months,
and 36 months from the index ablation, the RFA-CF group
had a numerically lower rate of use of antiarrhythmic at discharge (63.3% vs 71.6%, p 0.053) and at 36 months (7.1% vs

Type of ablation
p value

p value

RFA-nCF*

RFA-CF

(682)

(139)

Pericardial effusion
Tamponade or required drainage
Infection
Stroke/TIA

8 (1.2%)
7 (1.0%)
3 (0.4%
3 (0.4%)

5 (3.6%)
4 (2.9%)
1 (0.7%)
0 (0.0%)

0.04
0.10
0.53
> 0.99

4 (3.0%)
2 (1.5%)
0 (0.0%)
1 (0.7%)

0.12
0.65
> 0.99
0.52

Vascular bleeding
Non-vascular bleeding
Respiratory failure
Phrenic nerve injury
Pericarditis
30-day rehospitalization
30-day mortality

31 (4.5%)
6 (0.9%)
16 (2.3%)
0 (0.0%)
14 (2.1%)
75 (11.0%)
4 (0.6%)

2 (1.4%)
0 (0.0%)
5 (3.6%)
0 (0.0%)
5 (3.6%)
16 (11.5%)
1 (0.7%)

0.10
0.60
0.39
0.27
0.86
> 0.99

6 (4.4%)
2 (1.5%)
1 (0.7%)
3 (2.2%)
0 (0.0%)
14 (10.4%)
0 (0.0%)

0.96
0.63
0.33
< 0.01
0.14
0.83
> 0.99

*

CBA
(135)

Reference group

CBA cryoballoon ablation; RFA-CF radiofrequency ablation-contact force; RFA-nCF radiofrequency ablationnon-contact force; TIA transient ischemic attack
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13.2%, p 0.26) when compared to RFA-nCF group
(Supplementary material online, Table S3).
3.3.3 Long-term atrial fibrillation recurrence rate
The follow-up duration of the RFA-nCF group was longer
compared to RFA-CF group (41.2 SD 12.5 vs 31.8 SD 9.8
months, p < 0.01). On the other hand, there was no difference
in follow up between the RFA-nCF and CBA groups (41.2
SD12.5 vs 41.4 SD 14.6 months, p 0.81). AF recurrence rate
for the whole cohort was 27.5% in the first year and 45.1%
after long-term follow-up. Long-term recurrence rate of AF is
significantly lower in the CBA group when compared to
RFA-nCF and RFA-CF (33.3% vs 47.7% vs 43.9%, p <
0.01) (Fig. 1a). This finding did not change after adjustment
for baseline characteristics (Fig. 1b) or when analysis was
performed in patients with paroxysmal AF (Supplementary
material online, Fig. S1). On the other hand, in patients with

non-paroxysmal atrial fibrillation, there was no difference in
recurrence rate between the three groups. When analysis was
restricted for first time ablation of paroxysmal atrial fibrillation (excluded patients with prior ablation for AF) and only
PVI (excluded patients who underwent additional left atrial
ablation to PVI), findings remained consistent, with longterm recurrence rate of AF being significantly lower in the
CBA group when compared to RFA-nCF (22% vs 42%, HR
0.41, 95% CI 0.25–0.69, p < 0.01) and no difference in recurrence rate between RFA-CF and RFA-nCF (36% vs 42%, HR
0.86, 95% CI 0.55–1.34, p 0.51) (Supplementary material
online, Fig. S2).
Table 3 summarizes the hazard ratios and confidence intervals for AF recurrence rate adjusted for follow-up time using
Cox-regression analysis before and after adjustment for baseline characteristics. Long-term recurrence of AF was lower in
CBA group compared to RFA-nCF (HR 0.60, 95% CI 0.44–
0.83, p < 0.01). However, it was similar between the RFAnCF and RFA-CF groups (HR 1.01, 95% CI 0.76–1.33, p
0.96).

4 Discussion

Fig. 1 First recurrence after atrial fibrillation ablation. a Unadjusted
Kaplan-Meier curves of atrial fibrillation recurrence. b Time to first recurrence curves adjusted for baseline characteristics using Cox-regression
analysis

In this contemporary, real-world chart review study comparing the three major AF ablation technologies available for
percutaneous catheter PVI, the main findings were: (1) 30day complication rate between CBA and RFA was comparable with the exception of higher incidence of transient PNI in
CBA and higher incidence of pericardial effusion in RFA-CF
group; (2) less DCCV was utilized in the blanking period for
the CBA group; and (3) long-term recurrence of AF was significantly lower with CBA when compared to RFA with or
without the use of CF, with a lower rate of redo ablation and
similar rates of repeat DCCV. An important strength of this
study is its use of the VA healthcare system, which provided
important follow-up data on patients even when they changed
cities or state; this level of follow-up is generally limited in
other healthcare systems.
PVI is currently the standard strategy for any catheterbased treatment for patients with AF [1]. The standard point
by point RFA technique has been utilized for the last two
decades but still can be challenging and time-consuming.
Cryoballoon ablation has emerged as a novel treatment for
PVI as a single application for the last decade. CBA performed with the second-generation CB results in a shorter
procedure with less catheter time in the left atrium when compared to RFA [5]. Contact sensing RFA catheters have also
emerged as tools to allow for the optimization of each individual RF application that aims to maximize efficacy and procedural safety [3]. PVI has been used in the USA off label for
persistent AF, and several studies showed similar outcome
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Table 3

Long-term outcomes compared to non-contact force radiofrequency ablation group
Unadjusted

Adjusted

RFA-CF*

AF recurrence
Paroxysmal
Non-paroxysmal
*

CBA*

RFA-CF*

CBA*

HR (95% CI)

p value

HR (95% CI)

p value

HR (95% CI)

p value

HR (95% CI)

p value

1.05 (0.80–1.38)
0.95 (0.66–1.37)
1.19 (0.79–1.80)

0.73
0.78
0.41

0.59(0.43–0.81)
0.51 (0.34–0.76)
0.82 (0.50–1.35)

< 0.01
0.01
0.44

1.01 (0.76–1.33)
0.98 (0.67–1.44)
0.98 (0.64–1.51)

0.97
0.93
0.93

0.60 (0.44–0.83)
0.56 (0.37–0.84)
0.64 (0.38–1.07)

< 0.01
0.01
0.09

Compared to RFA-nCF group

AF atrial fibrillation; CBA cryoballoon ablation; CI confidence interval; HR hazard ratio; RFA-CF radiofrequency ablation-contact force; RFA-nCF
radiofrequency ablation-non-contact force

between CBA and RFA [6, 7]. Head to head comparisons of
these three ablation approaches are sparse.
In the original FIRE and ICE study comparing CBA and
RFA, there was no statistically significant difference of the
primary outcome (first documented recurrence of AF > 30
sec, documented occurrence of atrial flutter or atrial tachycardia, prescription of antiarrhythmic drugs, or redo AF ablation
after the 90-day blanking period) between the RFA and CBA
approaches [2]. However, additional analysis including the
blanking period and follow-up after the primary endpoint until
exiting the study showed that patients treated with CBA had
significantly lower redo ablation rates, DCCV, all-cause
rehospitalizations, and cardiovascular rehospitalizations compared to RFA (11.8% in the CBA arm required a redo ablation
procedure compared to 17.6% in RFA arm (p 0.03) after a
mean follow-up of 1.5 years) [8]. In the current study, 3% in
the CBA required a redo ablation in long-term follow-up.
DCCV was required in 3.7% in the CBA group during the
blanking period compared to 9.2% in the RFA-nCF group
(Supplementary material online, Table S2) suggesting that
CBA is less arrhythmogenic (less atrial arrhythmias during
the blanking period) than RFA. However, in patients who
underwent a redo procedure during follow-up, the rates of
atrial tachycardia or flutter was similar between the three
groups.
Ciconte et al showed that the rate of late PV reconnection in
CBA was low (22%, average of 1.25 PVs/patient) [9]. A later
study by Aryana et al. showed that CBA was associated with
more durable PVI when compared to non-contact force-guided RF ablation [10]. In the current study, only 4 patients in the
CBA group underwent redo ablation, and all of them required
additional PVI; however, we did not have data on the number
and laterality of the pulmonary veins that showed
reconnections; thus, we cannot draw conclusions about the
durability of PVI in this study. Nonetheless, it is important
to note that PVI was less frequently performed in patients
who underwent a redo ablation in the CF-RF group compared
to the nCF-RF group (87.5% vs 98.9%).

Prior data suggests that PVI can be achieved with the
second-generation CB alone in nearly all patients using the
second-generation device [2, 11, 12]. In our study, however,
additional RFA in left atrium was required in 6.7% undergoing CBA.
In the STOP AF post-approval study, which was a multicenter prospective study using second-generation CB for
drug-resistant symptomatic paroxysmal AF [13], freedom
from AF was 81.6% at 12 months, 73.8% at 24 months, and
68.1% (64.1%, from all atrial arrhythmias) at 36 months. The
results of the current study are in line with these results (87%
freedom from AF at one year and 72% with long-term followup).
An additional important finding in this study was the lack
of difference in AF recurrence rate between non-CF and CF
RFA ablations, with both being associated with higher recurrence when compared to CBA. Prior studies have largely suggested similar efficacy between CBA and nCF RFA, especially in randomized studies [2]. A meta-analysis comparing CF
vs non-CF-guided ablation found that CF-guided therapy was
associated with significant AF/atrial tachycardia-free survival
benefit in patient with paroxysmal AF over a median followup of 12 months [3]. However, in a more recent meta-analysis
by Virk et al., there was no difference in freedom from AF,
independent of AF type, when analysis was restricted to randomized trials [14]. In a recent randomized trial, Buist et al.
showed improved arrhythmia-free survival and more durable
PVI with the use of second-generation CBA compared to
RFA-CF in patients with drug-refractory paroxysmal AF, with
similar complication rates [15]. In a recently published individual patient data meta-analysis, CBA was associated with
less long-term failures in men but not in women when compared to RFA [16].
In patients with persistent atrial fibrillation, there was no
difference in AF recurrence rate between the three groups after
the index ablation even though the percentage of patients undergoing ablation beyond PVI was lower in CBA group compared to the other two groups. This finding is consistent with
the results of the STAR-AF II trial that showed no added
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reduction in the rate of AF recurrence when mitral or roof
linear ablation or CFAE was performed alongside PVI. [17]
In our study, the 30-day complication rate was generally
comparable to what was reported in previous studies [2, 18]
and among the three groups with the main exception of transient PNI that was significantly higher in CBA group.
However, the reported rate in our study (2.2%) was similar
to the FIRE and ICE study (2.7%) [2] and is much less compared to what has been reported in elsewhere (11.0% and
13.5% in some studies) [19]. One other interesting finding
was the higher incidence of pericardial effusion in the RFACF group when compared to the RFA-nCF group; however, it
was not statistically significant when only effusions requiring
intervention or causing tamponade were evaluated. This could
reflect the somewhat stiffer nature of the CF catheters and the
variable level of expertise of the operators in regard to the
required CF for the ablation. This finding supports the results
of a recent study which demonstrated a higher incidence of
cardiac tamponade in CF compared to non-CF ablation [20].
In our study, the incidence of pericardial effusion in CBA was
not better than RFA and was higher than reported in a recent
meta-nalysis [21].

at affiliated academic medical centers. The last two factors
likely resulted in underestimation of the actual number of
AF ablation procedures performed per site and operator. Due
to the reliance on medical records, we could not assess the
difference in radiation and intravenous contrast exposure
among these techniques as well as balloon inflation times
and freeze duration in CBA group. Finally, we were unable
to determine if stable and recommended CF was achieved
during the CF RFA procedures [18]. This may have affected
the efficacy of this procedure since recent studies suggested
better outcome when ablation index was used in the CF RFA
[23, 24].

6 Conclusion
In our real-world study of a predominantly male patient population, CBA for paroxysmal AF was associated with lower
incidence of AF recurrence and redo ablation rates during
long-term follow-up while having a comparable safety profile
compared to RFA independent of the use of CF catheters.
These results should be validated in a prospective manner to
evaluate if outcomes will be different based on gender and
type of AF.

5 Limitations
Our study has several limitations. Data collection relied on
retrospective chart review of the VA health records system.
However, it still provides important patient level data that
cannot be obtained in studies based only on ICD codes. As
in any retrospective study, selection and other bias may have
impacted the results. Adjudication of type of AF and AF recurrence rate was based on record review, and the true recurrence rate (especially asymptomatic) may be underestimated.
Although we could not account for any follow-up that happened outside the VA system, we believe the impact of this is
likely much lower when compared to other healthcare systems
as veterans tend to stay in the VA system even after moving to
a different city or state. Type of monitoring for arrhythmia
recurrence after the PVI was not standardized but reflects
real-world practice. As expected of an older US veteran population, the vast majority of patients was male, and results may
not be applicable to females. In fact, female gender has been
associated with more failed ablations and higher incidence of
complications and cardiovascular rehospitalization post-PVI
[22]. Ablations were performed in 34 centers and by operators
of varying experience especially with newer technologies.
Variation in the learning curve among newer ablation technologies could also have affected the procedure outcome. We
could not adjust for these operator characteristics both due to
the low numbers per site and operator due to using only one
procedure CPT code as well as the practical observation that
most operators within the VA system often perform ablations
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